Cajal Neuroscience
- Company typePrivate
- Founded2022
- HeadquartersSeattle, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
Cajal Neuroscience firmographics
Firmographics- Name
- Cajal Neuroscience
- Legal name
- Cajal Therapeutics Inc.
- Website
- https://cajalneuro.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Cajal Neuroscience industry classification
Industry- Product category
- Neurodegenerative disease drug discovery
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Cajal Neuroscience is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cajal Neuroscience business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Cajal Neuroscience product offering
Product offeringCore offering
Cajal Neuroscience is a discovery-stage biotech developing small molecule and RNA medicines that restore iron homeostasis across systemic and neurologic diseases. Its lead program CTX001 is a first-in-class iron mobilizer designed to restore iron transport and make iron available to metabolic and cellular processes, with pipeline indications spanning anemias of inflammation, neurodegenerative diseases, and iron-related disorders.
Differentiator
Problem solved
Functional benefit
Products and services
- CTX001 CTX001 is Cajal's lead program — a first-in-class iron mobilizer intended to restore iron transport and make iron available again to key metabolic and cellular processes, addressing anemias of inflammation, neurodegenerative diseases, and other iron-related disorders.
Companies that use Cajal Neuroscience
Customer profileSegments2 records
Ideal customer profiles1 record
Cajal Neuroscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Cajal Neuroscience partnerships and signals
Strategic signalScale indicators1 record
Cajal Neuroscience competitors and assessment
Company assessmentDirect peers
- Denali Therapeutics: Clinical-stage biotech developing small molecule and biologic therapies for neurodegenerative diseases including Parkinson's and Alzheimer's. Highly comparable to Cajal given overlapping CNS indication focus and multi-modality small molecule/RNA biologics approach.
- Prothena Corporation: Biotech focused on protein dysregulation in neurodegenerative diseases such as Parkinson's and Alzheimer's. Comparable to Cajal as a CNS-focused drug discovery company targeting novel mechanisms in neurodegeneration.
- Wave Life Sciences: Clinical-stage RNA medicines company with programs in Huntington's disease, ALS, and other CNS indications. Directly comparable to Cajal's RNA medicine modality applied to neurodegeneration.
- Acumen Pharmaceuticals: Clinical-stage biotech developing disease-modifying therapeutics for Alzheimer's disease. Overlaps with Cajal's neurodegeneration focus on Alzheimer's using a novel mechanistic approach.
Broad incumbents
- Ionis Pharmaceuticals: Established RNA-targeted therapeutics company with multiple approved drugs and a CNS pipeline. Cajal's RNA medicines approach shares platform modality with Ionis, though Ionis is broader and commercial-stage.
- Alnylam Pharmaceuticals: Leading RNAi therapeutics company with approved products and an emerging CNS push. Comparable platform modality to Cajal's RNA medicines, though more mature and commercial.
Emerging players
- Vanqua Bio: Early-stage neuroscience biotech developing small molecule therapies for CNS disorders. Comparable to Cajal as a fellow emerging neuroscience drug discovery company at similar stage.
- Clene Nanomedicine: Clinical-stage company developing nanocatalytic therapeutics for neurodegenerative diseases including ALS and MS. Comparable emerging CNS-focused biotech addressing neurodegeneration through novel mechanisms.
- Karuna Therapeutics: CNS-focused biotech (acquired by BMS in 2024) that developed a novel CNS mechanism through clinical proof-of-concept. Relevant comparable demonstrating the BMS neurology partnership/acquisition pathway available to Cajal.
Others
- Evotec SE: Drug discovery and development platform company and a Cajal Series A investor. Evotec is both a comparable infrastructure/platform peer and a strategic collaborator given its investment stake.
Market position
Customer concentration
Cajal Neuroscience social profiles
Digital presenceCajal Neuroscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cajal Neuroscience leadership team
Management profileNumber of profiles
Profiles6 records
Cajal Neuroscience funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cajal Neuroscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cajal Neuroscience
What does Cajal Neuroscience do?
Cajal Neuroscience is a discovery-stage biotech developing small molecule and RNA medicines that restore iron homeostasis across systemic and neurologic diseases. Its lead program CTX001 is a first-in-class iron mobilizer designed to restore iron transport and make iron available to metabolic and cellular processes, with pipeline indications spanning anemias of inflammation, neurodegenerative diseases, and iron-related disorders.
Is Cajal Neuroscience a public or private company?
Cajal Neuroscience is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cajal Neuroscience founded?
Cajal Neuroscience was founded in 2022. It employs 51 to 100 people.
Where is Cajal Neuroscience based?
Cajal Neuroscience is headquartered in Seattle, United States, in the North America region.
Who are Cajal Neuroscience's main competitors?
Direct peers on record are Denali Therapeutics, Prothena Corporation, Wave Life Sciences and Acumen Pharmaceuticals. Broad incumbents are Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Emerging players are Vanqua Bio, Clene Nanomedicine and Karuna Therapeutics. Evotec SE is listed as an others.
Does Cajal Neuroscience have an API?
No public API is recorded for Cajal Neuroscience.
What industry is Cajal Neuroscience in?
Cajal Neuroscience's product category is Neurodegenerative disease drug discovery. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals.